Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease

Muscle and Nerve

Volumn 37, Issue 3, 2008, Pages 350-357

  Martinuzzi, Andrea ^a   Liava, Alexandra ^a   Trevisi, Enrico ^a   Frare, Mara ^a   Tonon, Caterina ^b   Malucelli, Emil ^b   Manners, David ^b   Kemp, Graham J ^c   Testa, Claudia ^b   Barbiroli, Bruno ^b   Lodi, Raffaele ^b  

^a SCIENTIFIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

ACE inhibitor; McArdle's disease; Muscle glycogenosis; Ramipril; Therapeutic trial

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; PLACEBO; RAMIPRIL;

ADULT; ARTICLE; BICYCLE ERGOMETER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; EXERCISE TOLERANCE; FEMALE; FUNCTIONAL ASSESSMENT; GENE DELETION; GENE INSERTION; GENOTYPE; GLYCOGEN STORAGE DISEASE TYPE 5; HAPLOTYPE; HUMAN; MALE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36; WORLD HEALTH ORGANIZATION DISABILITY ASSESSMENT SCALE II;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PHOSPHORUS ISOTOPES; PILOT PROJECTS; QUALITY OF LIFE; RAMIPRIL; RETROSPECTIVE STUDIES;

EID: 39749147331     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20937     Document Type: Article

References (31)

1. Apolone G, Mosconi P. The Italian SF-36 survey: translation, validation and norming. J Clin Epidemiol 1998;51:1025-1036.
2. Bendahan D, Kemp G, Roussel M, Fur YL, Cozzone PJ. ATP synthesis and proton handling in short periods of exercise and subsequent recovery. J Appl Physiol 2003;94:2391-2397.
3. Chwastiack LA, Von Korff M. Disability in depression and back pain evaluation of the World Health Organization Disability Assessment Schedule (WHO DAS II) in a primary care setting. J Clin Epidemiol 2003;56:507-524.
4. 2max or mechanical efficiency in women. Eur J Appl Physiol 2007;99:11-18.
5. Dietze GJ, Wicklmayr M, Rett K, Jacob S, Henriksen EJ. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 1996;45(suppl):S110- S114.
6. Di Mauro S, Tsujino S. Non-lysosomal glycogenoses. In: Engel AG, Franzini-Armstrong C (eds): Myology, 2nd edition. New York: McGraw-Hill; 1994, p 1554-1576.
7. Dragovich T, Minhall R, Jackman HL, Wang LX, Erdos EG. Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes 1996;1(suppl):S34-S37.
8. Frossard M, Joukhadar C, Steffen G, Schmid R, Eichler HG, Muller M. Paracrine effects of angiotensin-converting-enzyme and angiotensin-II-receptor inhibition on transcapillary glucose transport in humans. Life Sci 2000;66:PL147-PL154.
9. Gomez-Gallego F, Santiago C, Moran M, Perez M, Matè-Muñoz JL, Fernandez del Valle M, et al. The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease. Br J Sports Med, July 6, 2007 [Epub ahead of print].
10. Gordon S, Davis BS, Carlson CJ, Booth FW. Ang II is required for optimal overload-induced skeletal muscle hypertrophy. Am J Physiol 2001;280:E150-E159.
11. Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 2006;59:922-928.
12. Jones A, Woods DR. Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol 2003;35:855-866.
13. Lodi R, Tonon C, Valentino ML, Iotti S, dementi V, Malucelli E, et al. Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy due to the common c.2708-2711delTTAG deletion. Ann Neurol 2004;56:719-723.
14. Lucia A, Matè-Muñoz JL, Pérez M, Foster C, Gutierrez-Rivas E, Arenas J. Double trouble (McArdle's disease and myasthenia gravis): how can exercise help? Muscle Nerve 2007;35:125-128.
15. Martin MA, Rubio JC, Buchbinder J, Fernandez-Hojas R, del Hoyo P, Teijeira S, et al. Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study. Ann Neurol 2001;50:574-581.
16. Martinuzzi A, Sartori E, Fanin M, Nascimbeni A, Valente L, Angelini C, et al. Phenotype modulators in myophosphorylase deficiency. Ann Neurol 2003;53:497-502.
17. Mat'-Muñoz JL, Moran M, Perez M, Chamorro-Viña C, Goinez-Gallego F, Santiago C, et al. Favorable responses to acute and chronic exercise in McArdle's patients. Clin J Sports Med 2007;17:297-303.
18. Onder G, Penninx BWJH, Balkrishnan R, Fried LP, Chaves PH, Williamson J, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002;359:926-930.
19. Paradas C, Fernandez-Cadenas I, Gallardo E, Lligè D, Arenas J, Illa I, et al. Variable presentation of the clinical phenotype of McArdle's disease in a kindred harbouring a novel compound genotype in the muscle glycogen Phosphorylase gene. Neurosci Lett 2005;391:28-31.
20. Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000;102:35-41.
21. Predel HG, Rohden C, Heine O, Prinz U, Rost RE. ACE inhibition and physical exercise: studies on physical work capacity, energy metabolism, and maximal oxygen uptake in well trained, healthy subjects. J Cardiovasc Pharmacol 1994;23(suppl):S25-S28.
22. Quinlivan R, Beynon RJ. Pharmacological and nutritional treatment for McArdle's disease (glycogen storage type V). Cochrane Systematic Rev 2006;CD003458.
23. Rubio JC, Gomez-Gallego F, Santiago C, Garcia-Consuegra I, Perz M, Bariopedro MI, et al. Genotype modulators of clinical severity in McArdle disease. Neurosci Lett 2007;422:217-222.
24. The DREAM Trial Investigators. Effect of Ramipril on the incidence of diabetes. N Engl J Med 2006;355:1-12.
25. Vescovo G, Dalla Libera L, Serafini F, Leprotti C, Facchin L, Volterrani M, et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998;98:1742-1749.
26. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003;349:2503-2509.
27. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-483.
28. Weakers L, Bouhanick B, Hadjadj S, Gallois Y, Roussel R, Pean F, et al. Modulation of the renal response to ACE Inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes 2005;54:2961-2967.
29. WHO Mental Health Bulletin. A newsletter on noncommunicable diseases and mental health. WHO Mental Health Bulletin 2000;78:6-30.
30. Williams AG, Rayson MP, Jubb M, World M, Woods DR, et al. The ACE gene and muscle performance. Nature 2000;403:614.
31. Woods D, Onambele G, Woledge R, Skelton D, Bruce S, Humphries S, et al. Angiotensin-I converting enzyme genotype-dependent benefit from hormone replacement therapy in isometric muscle strength and bone mineral density. J Clin Endocrinol Metab 2001;86:2200-2204.